Medication info
Rozetel Tablets 40/5/10 Milligrams

Rozetel Tablets 40/5/10 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tabletEzetimibe›10mg / 1 tablet
Manufacturer / importer
Nokshim Co., Ltd.
Appearance
Yellow oval film-coated tablets
Packaging
30 tablets/box [6 tablets/PTP X 5]
Approval status
Active

MFDS item code 202106690 · Approved 2021.09.29 · Insurance code 643606250

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia (including hypercholesterolemia), prevention of cardiovascular disease
Who takes it
Adults
Adult dose
This drug is for use only in adults. The dose should be individualized for each patient based on the efficacy and tolerability of telmisartan and the rosuvastatin/ezetimibe combination. Take 1 tablet once daily with water, with or without food. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. Telmisartan produces an additional blood pressure-lowering effect when administered concomitantly with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg of telmisartan orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting telmisartan to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. • Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin/ezetimibe The rosuvastatin/ezetimibe combination is administered once daily, with or without food. Patients should continue a standard cholesterol-lowering diet before and during treatment with the rosuvastatin/ezetimibe combination. The dose of the rosuvastatin/ezetimibe combination should be adjusted according to the patient's baseline LDL cholesterol level, recommended treatment goal, and response. Primary hypercholesterolemia The dose range of the rosuvastatin/ezetimibe combination is 5/10mg∼20/10mg once daily. The recommended initial dose is 5/10mg once daily. The dose may be adjusted for patients requiring a greater reduction in LDL cholesterol. After starting the rosuvastatin/ezetimibe combination or adjusting the dose, measure blood lipid levels at intervals of at least 4 weeks and adjust the dose accordingly; the dose may be increased to a maximum of 20/10mg once daily. For patients taking telmisartan and the rosuvastatin/ezetimibe combination concomitantly, switching to this drug (a combination tablet containing the same amounts of each active ingredient) may be considered for convenience.

Ingredients

Manufacturer
Nokshim Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia (including hypercholesterolemia), prevention of cardiovascular disease

  • Essential hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attacks
  • clinical evidence of end-organ damage
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial hyperlipidemia
  • non-familial hyperlipidemia
  • mixed dyslipidemia
  • elevated total cholesterol
View approved original text

This medication is only used for patients who must be treated with a combination of telmisartan and rosuvastatin/ezetimibe. Telmisartan is primarily used for the treatment of essential hypertension and reduces the risk of myocardial infarction, stroke, and death from cardiovascular disease in patients over the age of 55 who are at high risk for cardiovascular disease. Rosuvastatin/ezetimibe helps control cholesterol levels in patients with primary hypercholesterolemia or mixed dyslipidemia. Specifically, it reduces total cholesterol, LDL cholesterol, apo B protein, triglycerides, and non-HDL cholesterol while increasing HDL cholesterol, thereby supporting cardiovascular health. This medication is effectively used in the treatment of these two conditions.

How to take

Adult dose

This drug is for use only in adults. The dose should be individualized for each patient based on the efficacy and tolerability of telmisartan and the rosuvastatin/ezetimibe combination. Take 1 tablet once daily with water, with or without food. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. Telmisartan produces an additional blood pressure-lowering effect when administered concomitantly with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg of telmisartan orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting telmisartan to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. • Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin/ezetimibe The rosuvastatin/ezetimibe combination is administered once daily, with or without food. Patients should continue a standard cholesterol-lowering diet before and during treatment with the rosuvastatin/ezetimibe combination. The dose of the rosuvastatin/ezetimibe combination should be adjusted according to the patient's baseline LDL cholesterol level, recommended treatment goal, and response. Primary hypercholesterolemia The dose range of the rosuvastatin/ezetimibe combination is 5/10mg∼20/10mg once daily. The recommended initial dose is 5/10mg once daily. The dose may be adjusted for patients requiring a greater reduction in LDL cholesterol. After starting the rosuvastatin/ezetimibe combination or adjusting the dose, measure blood lipid levels at intervals of at least 4 weeks and adjust the dose accordingly; the dose may be increased to a maximum of 20/10mg once daily. For patients taking telmisartan and the rosuvastatin/ezetimibe combination concomitantly, switching to this drug (a combination tablet containing the same amounts of each active ingredient) may be considered for convenience.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during pregnancy, so it should be discontinued immediately if pregnancy is confirmed. Serious muscle issues may occur, so if muscle pain or weakness arises, consult a physician immediately. Individuals with liver dysfunction or a history of liver disease should consult healthcare professionals before taking this medication. This medication should not be used in patients with severely impaired kidney function or certain liver diseases. When combined with other medications, interactions may occur, so it is important to inform healthcare professionals about all medications taken. If a significant amount of alcohol is consumed or there is a history of liver disease, frequent liver function tests are required while taking this medication. This medication can lower blood pressure, so caution is needed if symptoms of dizziness or hypotension occur during treatment. There may be drowsiness or dizziness when driving or operating machinery, so caution is advised. There is a risk of hyperkalemia, so regular monitoring of serum potassium levels is essential. This medication may cause allergic reactions, so if symptoms such as rash, itching, or difficulty breathing occur, discontinue use immediately and notify healthcare professionals. Particularly, if liver enzyme levels are elevated in blood tests or muscle enzyme levels increase, treatment may need to be discontinued. The risk of muscle damage increases when used concurrently with fibrates, so co-administration should be avoided. Women of childbearing age should use appropriate contraceptive methods to avoid pregnancy while taking this medication. This medication contains lactose, so it should not be taken by patients with lactose intolerance. Adverse reactions reported include liver dysfunction, myalgia, gastrointestinal disturbances, headache, and dizziness; consult a healthcare professional if symptoms persist or worsen.

Side effects

Increased ALT, Increased AST, Increased Ɣ-GTP, Increased ALP, Abdominal pain, Oral ulcers, Vomiting, Chest pain, Palpitations, Dizziness, Difficulty breathing, Functional abnormalities of the Eustachian tube, Tympanic membrane perforation, Acute kidney injury, Hematuria, Shingles, Pneumonia, Non-small cell lung cancer, Hair loss, Dysuria, Rhinitis, Discomfort in the oropharynx, Lung disease, Unspecified inflammatory bowel disease, Benign gastrointestinal neoplasm, Hemorrhoids, Skeletal pain, Osteoporosis, Sensory loss, Movement disorders, Atherosclerosis, Frequent urination, Tinnitus, Hearing loss, Bad breath, Fatty liver, Chest pain, Facial swelling, Strange sensation, Drug intolerance, Irritable bowel syndrome, Esophagitis, Somnolence, Neurodegenerative disorders, Postural dizziness, Migraine, Diabetes, Impaired glucose tolerance, Depression, Bronchitis, Cystitis, Nail fungal infection, Soft tissue inflammation, Hepatic steatosis, Liver dysfunction, Hepatotoxicity, Acute hepatitis, Toxic hepatitis, Increased gamma-glutamyl transferase, Increased blood cholesterol, Increased blood alkaline phosphatase, Irregular heart rate, Osteoarthritis, Musculoskeletal stiffness, Musculoskeletal discomfort, Muscle weakness, Diaphoresis, Dermatitis, Skin burning sensation, Skin disorders, Alopecia, Oropharyngeal pain, Nasal congestion, Respiratory distress, Pelvic pain, Breast cysts, Ptosis, Diabetic retinopathy, Ear discomfort, Renal dysfunction, Benign esophageal neoplasm, Upper respiratory infection, Urinary tract infection, Sepsis, Anemia, Thrombocytopenia, Eosinophilia, Hypersensitivity, Anaphylactic reaction, Hyperkalemia, Hypoglycemia, Depression, Insomnia, Anxiety, Syncope, Visual disturbances, Dizziness, Bradycardia, Tachycardia, Hypotension, Orthostatic hypotension, Abdominal pain, Diarrhea, Dyspepsia, Abdominal fullness, Abdominal discomfort, Dry mouth, Abnormal liver function, Liver impairment, Increased sweating, Itching, Rash, Erythema, Angioedema, Drug rash, Toxic skin rash, Eczema, Urticaria, Myalgia, Lumbago, Muscle spasms, Arthralgia, Limb pain, Tendon pain, Acute kidney failure, Weakness, Influenza-like illness, Increased serum creatinine, Increased serum uric acid, Elevated serum creatine kinase, Decreased hemoglobin, Headache, Facial spasms, Sensory disturbances, Paralysis, Cough, Hyperventilation, Pneumonia, Flushing, Erectile dysfunction, Weakness, Edema, Decreased libido, Facial edema, Conjunctivitis, Tinnitus, Petechiae, Polyneuropathy, Memory loss, Peripheral neuropathy, Diarrhea, Thrombocytopenia, Jaundice, Hepatitis, Stevens-Johnson syndrome, Eosinophilia and systemic symptoms associated drug reaction syndrome, Lupus-like syndrome, Muscle rupture, Arthralgia, Immune-mediated necrotizing myopathy, Hematuria, Edema, Depression, Sleep disorders, Gynecomastia, Fatal and non-fatal liver failure, Memory impairment, Amnesia, Memory loss syndrome, Memory disorders, Confusion, Myasthenia gravis, Ocular myasthenia, Chest discomfort, Anorexia, Abdominal distension, Abnormal liver function tests, Syncope, Systemic pain, Muscle spasms, Gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is recommended to maintain a storage temperature between 1 and 30 degrees Celsius to preserve the medication's effectiveness.

Appearance and packaging

Appearance

Yellow oval film-coated tablets

Package unit

30 tablets/box [6 tablets/PTP X 5]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.